These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22896002)

  • 1. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.
    Hivert B; Caron C; Petit S; Charpy C; Fankam-Siaka C; Lecocq S; Zawadzki C; Susen S; Rusu M; Duhamel A; Tournilhac O; Goudemand J; Morel P
    Blood; 2012 Oct; 120(16):3214-21. PubMed ID: 22896002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VWF, WM, and angiogenesis: is there a link?
    Kastritis E; Dimopoulos MA
    Blood; 2012 Oct; 120(16):3163-4. PubMed ID: 23086619
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis.
    Okubo N; Sugawara S; Fujiwara T; Sakatsume K; Doman T; Yamashita M; Goto K; Tateishi M; Suzuki M; Shirakawa R; Eura Y; Kokame K; Hayakawa M; Matsumoto M; Kawate Y; Miura M; Takiguchi H; Soga Y; Shirai S; Ando K; Arai Y; Nakayoshi T; Fukumoto Y; Takahama H; Yasuda S; Tamura T; Watanabe S; Kimura T; Yaoita N; Shimokawa H; Saiki Y; Kaikita K; Tsujita K; Yoshii S; Nakase H; Fujimaki SI; Horiuchi H
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102284. PubMed ID: 38268521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
    Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ABO blood group on von Willebrand factor tests in healthy Saudi blood donors.
    Alharbi A; Hassan SB; Al-Momen AK; Al-Saleh K; Nasr R; Kohgear H; Owaidah T
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):211-215. PubMed ID: 29369083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease.
    Verfaillie CJ; De Witte E; Devreese KM
    Int J Lab Hematol; 2013 Oct; 35(5):555-65. PubMed ID: 23551532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
    Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
    Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Content and functional activity of von Willebrand factor in apheresis plasma.
    Burnouf T; Caron C; Burkhardt T; Goudemand J
    Vox Sang; 2004 Jul; 87(1):27-33. PubMed ID: 15260819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo).
    Mohammed S; Favaloro EJ
    Methods Mol Biol; 2017; 1646():435-451. PubMed ID: 28804846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.